Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Fibrosis: early-phase trial registry

5 of 11 indexed Fibrosis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 5 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Fibrosis: 11 US clinical trials tracked, 5 recruiting.

Fibrosis is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition fibrosis

OPEN 5 | RECR 45% | LATE 0 | EARLY 7 | RANK #1577 | SPON 3

Nearest open-share peer: Advanced Breast Carcinoma (45% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Fibrosis (this)45%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Fibrosis

Fibrosis lists 5 open slots (45% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fibrosis recruits in line with its size-band peers.

    5 of 11 indexed trials (45.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Fibrosis research.

    M.D. Anderson Cancer Center accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Fibrosis enrolment sits around 59 participants.

    Median target enrolment is 59 among the 11 trials that report a genuine target (sentinel values excluded). 6 of those (54.5%) plan for fewer than 100 participants.

  4. Fibrosis research is mostly interventional.

    9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 26

Open and recent trials

11 total, page 1 of 1

RECRUITING 1,000 participants

Blood Collection Biorepository for Liver Disease Research

State University of New York at Buffalo

NCT03025074

RECRUITING Phase 2 295 participants

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

M.D. Anderson Cancer Center

NCT06494111

RECRUITING Phase 2 250 participants

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

M.D. Anderson Cancer Center

NCT06912763

RECRUITING NA 30 participants

Copper Supplementation in Cirrhosis

University of Washington

NCT07471542

RECRUITING Phase 2 20 participants

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Pulmovant

NCT07333183

ACTIVE NOT RECRUITING Phase 2 135 participants

A Study of Mosliciguat in PH-ILD

Pulmovant

NCT06635850

ACTIVE NOT RECRUITING NA 24 participants

Manual Therapy in Treating Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors

M.D. Anderson Cancer Center

NCT03612531

COMPLETED Phase 2 318 participants

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Conatus Pharmaceuticals

NCT02686762

COMPLETED 59 participants

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

Rush University Medical Center

NCT01296529

COMPLETED Phase 2 50 participants

Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis

National Cancer Institute (NCI)

NCT00001437

COMPLETED Phase 1 33 participants

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

Bristol-Myers Squibb

NCT03142165

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6

Named interventions

Most-linked intervention names on Fibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dry Powder Inhaler Device
2 trials
Pentoxifylline Drug
2 trials
Placebo Drug
2 trials
pentoxifylline Drug
1 trials
Emricasan (50 mg) Drug
1 trials
Emricasan (5 mg) Drug
1 trials
BMS-986263 Drug
1 trials
Manual Therapy Procedure
1 trials

US sites by state

Facility locations filed on Fibrosis trials. A trial with sites in several states counts in each.

Texas 4 trials
Florida 3 trials
California 3 trials
Illinois 2 trials
Arizona 2 trials
Washington 1 trials
Utah 1 trials
South Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fibrosis page

11 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fibrosis condition card totals 11 registered trials; most-linked intervention Dry Powder Inhaler; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.